Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Prime-Boost Influenza Vaccination
NCT02557802Completed
- Sponsor
- University of Surrey
- Start
- Oct 2015
- Primary completion
- Jan 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of live attenuated influenza vaccine and Fluarix Quadrivalent in influenza (2 arms), sponsored by University of Surrey. Primary endpoint: Breadth of T-cell responses at 8 months. Started Oct 2015; status: completed.
02
Drugs
live attenuated influenza vaccineFluarix Quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02557802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557802.